Letter

HIV

The societal costs of failing to develop a vaccine

BMJ 2007; 335 doi: 10.1136/bmj.39269.490255.BE (Published 12 July 2007)
Cite this as: BMJ 2007;335:60.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Jeremiah Norris, director
  1. Center For Science in Public Policy, Hudson Institute, Washington, DC 20005, USA
  1. Jeannie{at}hudson.org

    Policymakers should consider not the cost of developing a vaccine against HIV, but the cost to society if it fails to develop one.1

    In the developed world, some patients on antiretroviral treatment will develop drug resistance and the number will be cumulative each year. Medical care costs will increase exponentially for drug …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular